Skip to main content
. Author manuscript; available in PMC: 2022 Apr 19.
Published in final edited form as: Am J Perinatol. 2020 Oct 19;39(6):658–665. doi: 10.1055/s-0040-1718581

Table 4.

LDA and mode of delivery: intent-to-treat analysis, participants with complete follow-up (n = 1,069)

Percent with cesarean by treatment group
LDA
% (n/N)		 Placebo
% (n/N)		 RR (95% CI) p-Value
Cesarean versus vaginal birth 15.7 (83/529) 13.5 (73/540) 1.02 (0.98, 1.07) 0.31
Cesarean versus vaginal birth by prior cesarean
Prior cesarean 50.0 (40/80) 47.0 (39/83) 1.03 (0.88, 1.20) 0.70
No prior cesarean 9.6 (43/449) 7.4 (34/457) 1.02 (0.99, 1.06) 0.25
Cesarean versus vaginal birth by parity
Nulliparous 15.1 (36/239) 9.6 (24/249) 1.06 (1.00, 1.12) 0.07
Parous 16.2 (47/290) 16.8 (49/291) 0.99 (0.94, 1.06) 0.84

Abbreviations: CI, confidence interval; LDA, low-dose aspirin; n, number with cesarean delivery; N, total number of live births; RR, relative risk.